TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lupin Limited ( (IN:LUPIN) ) has shared an announcement.
Lupin Limited announced that the U.S. FDA conducted an inspection at its manufacturing facility in Goa, India, resulting in a Form-483 with seven observations. The company is committed to addressing these observations and maintaining compliance with CGMP standards, which is crucial for its operational integrity and market reputation.
More about Lupin Limited
Lupin Limited operates in the pharmaceutical industry, focusing on the development, production, and marketing of a wide range of generic and branded formulations and active pharmaceutical ingredients. The company is a significant player in the global pharmaceutical market, with a strong emphasis on compliance and quality standards.
Average Trading Volume: 22,008
Technical Sentiment Signal: Strong Buy
Current Market Cap: 925B INR
See more insights into LUPIN stock on TipRanks’ Stock Analysis page.